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ABBREVIATIONS

ABSTRACT

AND ACRONYMS

Cardiovascular diseases (CVDs), principally ischemic heart disease (IHD) and stroke, are the leading cause of

AC = alcoholic cardiomyopathy

global mortality and a major contributor to disability. This paper reviews the magnitude of total CVD burden,

AF = atrial ﬁbrillation

including 13 underlying causes of cardiovascular death and 9 related risk factors, using estimates from the

AFL = atrial ﬂutter

Global Burden of Disease (GBD) Study 2019. GBD, an ongoing multinational collaboration to provide

BMI = body mass index

comparable and consistent estimates of population health over time, used all available population-level data

CAVD = calciﬁc aortic valve

sources on incidence, prevalence, case fatality, mortality, and health risks to produce estimates for 204

disease

countries and territories from 1990 to 2019.

CHA = congenital heart

Prevalent cases of total CVD nearly doubled from 271 million (95% uncertainty interval [UI]: 257 to

anomalies

285 million) in 1990 to 523 million (95% UI: 497 to 550 million) in 2019, and the number of CVD deaths

CKD = chronic kidney disease

steadily increased from 12.1 million (95% UI:11.4 to 12.6 million) in 1990, reaching 18.6 million (95% UI: 17.1 to

CVD = cardiovascular disease

19.7 million) in 2019. The global trends for disability-adjusted life years (DALYs) and years of life lost also

DALYs = disability-adjusted

increased signiﬁcantly, and years lived with disability doubled from 17.7 million (95% UI: 12.9 to 22.5 million) to

life years

34.4 million (95% UI:24.9 to 43.6 million) over that period. The total number of DALYs due to IHD has risen

GBD = Global Burden of

steadily since 1990, reaching 182 million (95% UI: 170 to 194 million) DALYs, 9.14 million (95% UI: 8.40 to

Diseases, Injuries, and Risk
Factors Study

9.74 million) deaths in the year 2019, and 197 million (95% UI: 178 to 220 million) prevalent cases of IHD in

HAP = household air pollution

2019. The total number of DALYs due to stroke has risen steadily since 1990, reaching 143 million (95% UI: 133

HHD = hypertensive heart

to 153 million) DALYs, 6.55 million (95% UI: 6.00 to 7.02 million) deaths in the year 2019, and 101 million (95%

disease

UI: 93.2 to 111 million) prevalent cases of stroke in 2019.

HICs = high-income countries

Cardiovascular diseases remain the leading cause of disease burden in the world. CVD burden continues its

ICD = International

decades-long rise for almost all countries outside high-income countries, and alarmingly, the age-standardized

Classiﬁcation of Diseases

rate of CVD has begun to rise in some locations where it was previously declining in high-income countries.

IHD = ischemic heart disease

There is an urgent need to focus on implementing existing cost-effective policies and interventions if the world

IKF = impaired kidney function

is to meet the targets for Sustainable Development Goal 3 and achieve a 30% reduction in premature mortality

IS = ischemic stroke

due to noncommunicable diseases. (J Am Coll Cardiol 2020;76:2982–3021) © 2020 The Authors. Published by

LDL = low-density lipoprotein

Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC

LMICs = low- and middle-

BY license (http://creativecommons.org/licenses/by/4.0/).

income countries

C

LPA = low physical activity

ardiovascular disease (CVD) remains a major

This paper explores CVD trends from 1990

cause of premature mortality and rising

to 2019 and examines the extent to which

health care costs (1,2). Cardiometabolic,

population growth and aging explain the

behavioral, environmental, and social risk factors

observed

are major drivers of CVD. Consistent, comparable,

regional patterns and how the epidemiology

and systematic analysis of long-term trends and pat-

of the disease itself is changing. These trends

terns in global CVD are essential to guide public pol-

show us where in the world CVD mortality

icy and provide benchmarks for decision makers.

and burden are increasing or declining and

Beginning with ischemic heart disease (IHD) and

where progress has stalled (3). For each of the

stroke, this article provides information on the

contributing causes of cardiovascular death

burden of CVD, including 13 underlying causes of car-

and risk factors examined, we identify which

diovascular death and 9 related risk factors at the

regions and countries have the highest and

global, regional, and national levels (Supplemental

lowest estimates of prevalent cases and

Figure 1).

number of deaths, as well as summary

Riyadh, Saudi Arabia;

yy

Inselspital, University Hospital Bern, Bern, Switzerland;

zz

trends,

sex

differences,

Tulane University School of Public Health and
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and

MV = mitral valve
PAD = peripheral artery
disease

PM = particulate matter
RHD = rheumatic heart disease
SBP = systolic blood pressure
SDI = sociodemographic index
TMREL = theoretical minimum
risk exposure level

UI = uncertainty interval
YLDs = years lived with
disability

YLLs = years of life lost
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measures including number of years of life lost
(YLLs), number of years lived with disability (YLDs),
and the magnitude and temporal trends in disabilityadjusted life years (DALYs) (1). For each section, the
article also addresses how the summary measures of
health and disease discussed inform investments in
cardiovascular research, their implications for clinical
and public health practice, and implications for
health system development and national and regional
policy.
To improve accessibility across a wide range of
audiences, we have structured the review such that
each section can be read independently for those
most interested in a subset of causes or risks. Discussion pertinent to each topic is included within

HIGHLIGHTS
 The burden of CVD, in number of DALYs
and deaths, continues to increase
globally.
 CVD burden attributable to modiﬁable
risk factors continues to increase
globally.
 Countries should invest in existing costeffective public health programs and
clinical interventions to target modiﬁable
risks, promote healthy aging across the
lifespan, and reduce disability and premature death due to CVD.

every section. This article is a collaborative effort
involving the Journal of the American College of Cardiology, the National Heart, Lung, and Blood Insti-

Myocardial infarction was deﬁned according to the

tute, and the Institute for Health Metrics and

Fourth Universal Deﬁnition of Myocardial Infarction

Evaluation at the University of Washington designed

and was adjusted to include out-of-hospital sudden

to provide crucial population-level information that

cardiac death. Stable angina was deﬁned according to

can guide action for CVD and risk factor prevention,

the Rose Angina Questionnaire. Stroke was deﬁned

treatment, and control (2).

according to the World Health Organization deﬁnition
and was estimated separately for 3 subcategories: 1)

GLOBAL BURDEN OF DISEASE

ischemic stroke (IS); 2) intracerebral hemorrhage; and

STUDY METHODS

3) subarachnoid hemorrhage (7). Lower extremity

GBD 2019 is a multinational collaborative research

ankle brachial index of <0.9. Symptomatic PAD was

study that estimates disease burden for every country

deﬁned as self-report of symptoms of claudication

in the world (1,4). The study is an ongoing effort,

among those with an ankle brachial index of <0.9.

peripheral artery disease (PAD) was deﬁned by an

updated annually, and is designed to allow for

Atrial ﬁbrillation (AF) and atrial ﬂutter (AFL) were

consistent comparison over time from 1990 to 2019,

deﬁned by electrocardiogram. Hypertensive heart

by age and sex, and across locations. The study pro-

disease (HHD) was deﬁned as symptomatic heart

duces standard epidemiological measures such as

failure due to the direct and long-term effects of hy-

incidence, prevalence, and death rates as well as

pertension. Cardiomyopathy was deﬁned as symp-

summary measures of health, such as DALYs. DALYs

tomatic heart failure due to primary myocardial

represent the sum of years of life lost prematurely

disease or toxin exposure to the myocardium, such as

and years lived with disability; can be estimated from

alcohol. Acute myocarditis was deﬁned as an acute

life tables, estimates of prevalence, and disability

and

weights; and may be expressed as counts or rates.

inﬂammation using health system administrative

Annual updates to the study include new diseases,

data. Endocarditis and rheumatic heart disease (RHD)

new data sources, and updates to methods. All results

were deﬁned by their clinical diagnosis. Estimates of

are available via the GBD Compare website (5), and all

RHD include cases identiﬁed by clinical history and

input data is identiﬁed via the Global Health Data

physical

Exchange website (6). The study is performed in

standard

compliance with Guidelines for Accurate and Trans-

disease.

time-limited

condition

examination,

due

including

echocardiographic

to

myocardial

auscultation

criteria

for

or

deﬁnite

parent Health Estimates Reporting (GATHER) guide-

Mortality was estimated by using vital registration

lines for reporting health estimates (1). Detailed

data coded to the International Classiﬁcation of Dis-

methods

ease (ICD) system or household mortality surveys

of

GBD

2019

are

reported

in

the

Supplemental Appendix and summarized here.
Each CVD cause and related health states were

known as verbal autopsy. Statistical methods were
used to increase the comparability of mortality data

identiﬁed with standard case deﬁnitions. IHD repre-

sources, including the reclassiﬁcation of codes that

sented acute myocardial infarction, chronic stable

are nonspeciﬁc or unspeciﬁed, noise reduction algo-

angina, chronic IHD, and heart failure due to IHD.

rithms, and Bayesian geospatial regression software
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(CODem, the cause of death ensemble model, Insti-

number of CVD deaths steadily increased from 12.1

tute for Health Metrics and Evaluation, Seattle,

million (95% UI: 11.4 to 12.6 million) in 1990, reaching

Washington) that used location-speciﬁc covariates to

18.6 million (95% UI: 17.1 to 19.7 million) in 2019

create smoothed time trends for 204 countries and

(Figure 1A). The global trends for DALYs and YLLs

territories by borrowing strength over age, space, and

also increased signiﬁcantly, and YLDs doubled from

time. GBD 2019 allowed for the production of esti-

17.7 million (95% UI: 12.9 to 22.5 million) to 34.4

mates with uncertainty intervals (UIs) for all locations

million

in every year, even when data were sparse or missing.

that period.

(95%

UI:

24.9

to

43.6

million)

over

Disease incidence and prevalence were produced by

At the country level, age-standardized mortality

using a broad range of population-representative data

rates for total CVD were highest in Uzbekistan, Solo-

sources identiﬁed by literature review and via study

mon Islands, and Tajikistan and were lowest in

collaborations, including scientiﬁc reports of cohorts

France, Peru, and Japan, where rates were 6-fold

and registries, population surveys, microdata from

lower in 2019. From 1990 to 2019, large declines in

registry and cohort studies, and health system

the age-standardized rates of death, DALYs, and

administrative data. Consistent disease estimates

YLLs, together with small gradual reductions in age-

were

state-

standardized rates for prevalent cases and YLDs,

transition disease modeling software, DisMod-MR

suggest that population growth and aging are major

(Institute for Health Metrics and Evaluation), and

drivers of the increase in total CVD (Figure 1B).

produced

Bayesian

by

using

epidemiologic

meta-regression

MR-BRT

In 2019, total CVD DALYs were higher in men than

(Institute for Health Metrics and Evaluation), that

women before age 80 to 84 years (Supplemental

adjusted for study-level differences in measurement

Figure 2). After this age, the pattern reverses. The

methods and case deﬁnitions. Risk factor exposures

sex differences in DALYs is most striking between

were estimated by using population-representative

ages 30 and 60 years (men greater) and age >80 years

survey

geospatial

(women greater). The excess CVD deaths in women

Gaussian process regression models that borrowed

beginning at ages 80 to 84 years should focus atten-

strength across time and geography.

tion to cause-speciﬁc mortality at older ages and have

and

surveillance

software,

data

and

DALYs were calculated as the sum of YLLs, based

implications for secondary prevention strategies.

on a reference maximum observed life expectancy,

Among women, the age-standardized rates for

and YLDs based on standardized disability weights

DALYs were highest in Central Asia, Oceania, North

for each health state. Population-attributable frac-

Africa and the Middle East, and Eastern Europe; and

tions were calculated independently by risk factor by

lowest in High-Income Asia Paciﬁc, Australasia, and

using risk exposures, estimates of relative risk based

Western Europe (Supplemental Figure 3). Among

on meta-analyses, and theoretical minimum risk

men, age-standardized rates for DALYs were highest

levels

pair.

in Central Asia, Eastern Europe, and Oceania; and

Adjustment was made for comorbidity by simulating

lowest in High-Income Asia Paciﬁc, Australasia,

40,000 individuals in each age-sex-country-year

Western Europe, and Andean Latin America. At the

exposed to the independent probability of acquiring

country level, the highest age-standardized rates

conditions based on their prevalence. The 95% UIs

were estimated for many of the islands of Oceania,

reported for each estimate used 1,000 draws from the

Uzbekistan, and Afghanistan, while the lowest rates

posterior distribution of models, reported as the 2.5th

for DALYs were seen in Japan, France, and Israel

determined

for

each

risk-outcome

and 97.5th values of the distribution. Age standardi-

(Supplemental Figure 4). These regional and national

zation was performed via the direct method, applying

differences in total CVD burden and mortality reﬂect

a global age structure from the year 2019. The Uni-

differences in prevalence of CVD risk factors as well

versity of Washington Institutional Review Board

as access to health care (8). Differences in access to

Committee approved the Global Burden of Diseases,

effective primary and secondary prevention strate-

Injuries, and Risk Factors Study (STUDY00009060).

gies may also play a role in differences in total CVD
burden, especially in low- and middle-income coun-

CARDIOVASCULAR DISEASES

tries (LMICs) (9).

TOTAL CVDs. CVDs are common, have poor survival,

plications for clinical practice and public health pol-

Global patterns of total CVD have signiﬁcant imand are increasing worldwide (Central Illustration).

icy development (10). Prevalent cases of total CVD are

Prevalent cases of total CVD nearly doubled from 271

likely to increase substantially as a result of popula-

million (95% UI: 257 to 285 million) in 1990 to 523

tion growth and aging, especially in Northern Africa

million (95% UI: 497 to 550 million) in 2019, and the

and Western Asia, Central and Southern Asia, Latin
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C E N T R A L IL L U ST R A T I O N Cardiovascular Disease Burden Across Time, Location, Cause, and
Risk Factor

Roth, G.A. et al. J Am Coll Cardiol. 2020;76(25):2982–3021.

Percent Change in Age-Standardized CVD Death Rate from 2010-2019. Map of the percent change in age-standardized CVD mortality rate
from 2010 to 2019.Number of CVD Deaths. Total number of deaths due to CVD by sex, 1990 to 2019; total number of deaths due to CVD in
2010 and 2019 among the countries with the highest number of CVD deaths in 2019. Proportion of CVD Deaths by Cause (2019). Proportion
of total CVD deaths in 2019 by underlying causes. CVD Burden Attributable to Modiﬁable Risk Factors. Comparison of the rankings of CVD
DALYs attributable to modiﬁable risk factors in 1990 and 2019. CVD ¼ cardiovascular disease; DALYs ¼ disability-adjusted life years; LDL ¼
low-density lipoprotein.
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F I G U R E 1 Total Numbers and Rates of Cardiovascular Diseases
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(A) Total number of DALYs, deaths, prevalent cases, YLDs, and YLLs due to cardiovascular diseases, 1990 to 2019. Shaded regions represent
95% uncertainty intervals. (B) Age-standardized and all-ages DALY, death, prevalence, YLD, and YLL rates of cardiovascular diseases, 1990
to 2019. Shaded regions represent 95% uncertainty intervals. DALYs ¼ disability-adjusted life years; YLDs ¼ years lived with disability;
YLLs ¼ years of life lost.
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America and the Caribbean, and Eastern and South-

on delivering effective interventions that will reverse

eastern Asia, where the share of older persons is

these trends, including those that prevent and control

projected to double between 2019 and 2050 (11,12).

diabetes, decrease obesity and high cholesterol,

Increased attention to promoting ideal cardiovascular

improve diet and physical activity, reduce tobacco

health and healthy aging across the lifespan is

and excessive alcohol use, integrate “polypills” for

necessary (13). Equally importantly, the time has

elevated blood pressure and related conditions,

come to implement feasible and affordable strategies

improve pre- and in-hospital care for acute coronary

for the prevention and control of CVD and to monitor

syndrome, and improve survival and quality of life for

results (14).

those living with the long-term sequelae of IHD,

ISCHEMIC HEART DISEASE. The total number of

including heart failure. Social and economic factors

DALYs due to IHD has risen steadily since 1990,

remain fundamental drivers of IHD, suggesting that

reaching 182 million (95% UI: 170 to 194 million)

multisectoral interventions are needed to eradicate

DALYs and 9.14 million (95% UI: 8.40 to 9.74 million)

this disease (15).

deaths in the year 2019 (Figure 2A). GBD 2019 esti-

STROKE. The total number of prevalent strokes,

mated 197 million (95% UI: 178 to 220 million) prev-

deaths, and DALYs due to stroke increased steadily

alent cases of IHD in 2019.

from 1990, reaching 101 million (95% UI: 93.2 to 111

Global age-standardized rates for DALYs, deaths,

million) prevalent (85.3% [95% UI: 82.6% to 88.2%]

and prevalent cases declined over this time period,

increase) stroke survivors, 6.55 million (95% UI: 6.00

indicating that, on average, global increases in IHD

to 7.02 million) deaths from stroke (43.3% [95% UI:

have been due to population growth and aging,

31.0% to 55.4%] increase), and 143 million (95% UI:

although even the age-standardized death rate is

133 to 153 million) DALYs due to stroke (32.4% [95%

estimated to be increasing in many locations across

UI: 22.0% to 42.2%] increase) in 2019, with the bulk of

South, East, and Southeastern Asia, including China

the

(Figure 2B). Increasing absolute numbers of incident

(Supplemental Figures 8A and 9A). Of 12.2 million

and prevalent IHD cases in most countries mean that

(95% UI: 11.0 to 13.6 million) incident stroke cases,

national

address

7.63 million (95% UI: 6.57 to 8.96 million) (62.4%)

increasing demand for IHD-related preventive and

were IS, 3.41 million (95% UI: 2.97 to 3.91 million)

therapeutic services as these trends continue.

(27.9%) were intracerebral hemorrhages, and 1.18

health

systems

will

need

to

At the global level, substantially more total DALYs

burden

million

(95%

outside

UI:

of

1.01

due to IHD were experienced by men than women.

were

subarachnoid

IHD DALYs rose rapidly for men beginning at age

Figures 10A, 11A, and 12A).

the

to

high-income

1.39

hemorrhages

million)

world

(9.7%)

(Supplemental

30 years (Supplemental Figure 5). Men ages 45 to

Globally, age-standardized rates for deaths and

49 years had almost as many DALYs due to IHD as

DALYs due to stroke substantially declined over the

women ages 65 to 69 years.

same period of time (Supplemental Figures 8B, 10B,

Age-standardized DALY rates due to IHD were

11B, and 12B), suggesting that: 1) preventive mea-

highest in Eastern Europe, Central Asia, Oceania, and

sures are very effective at lowering risk of both

the Middle East/North Africa regions (Supplemental

ischemic and hemorrhagic stroke; and 2) on average,

Figure 6). At the country level, extremely high rates

global increases in stroke burden have been largely

were estimated for Uzbekistan, Ukraine, Tajikistan,

due to population growth and aging. Importantly,

and many of the islands of Oceania, with the lowest

age-standardized rates for prevalence of stroke sur-

levels in Japan, Republic of Korea, and France

vivors have increased since 1990 in several locations

(Supplemental Figure 7). Higher exposure to risks

including in China, Indonesia, and parts of the United

including tobacco and excessive alcohol use and

States. Age-standardized death rates also increased in

restricted access to preventive health care may partly

some

explain these patterns.

Philippines.

locations,

including

Indonesia

and

the

IHD remains a major threat to public health, and

Age-standardized rates of DALYs and deaths due to

overall burden is increasing globally. In some loca-

stroke were substantially greater in men compared to

tions over the past 5 years, including parts of the

women, but prevalence was greater in women, sug-

United States and United Kingdom, age-standardized

gesting the possibility of greater risk of death and

IHD death rates are increasing, suggesting that long-

disability in men but better stroke survival in women.

term declines in IHD due to improved prevention

Similar patterns were observed in men and women

and health care are no longer occurring in these lo-

with IS, intracerebral hemorrhage, and subarachnoid

cations. Health systems and countries need to focus

hemorrhage.
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F I G U R E 2 Total Numbers and Rates of Ischemic Heart Disease
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(A) Total number of DALYs, deaths, prevalent cases, YLDs, and YLLs due to ischemic heart disease, 1990 to 2019. Shaded regions represent
95% uncertainty intervals. (B) Age-standardized and all-ages DALY, death, prevalence, YLD, and YLL rates of ischemic heart disease, 1990
to 2019. Shaded regions represent 95% uncertainty intervals. Abbreviations as in Figure 1.
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F I G U R E 3 Map of Age-Standardized Prevalence of Stroke Survivors in 2019

There is tremendous regional disparity in the burden

approaches for delivering stroke prevention that can

of stroke. Age-standardized rates of deaths and

reverse these trends, including strategies to provide

DALYs due to stroke were highest in Oceania, Central

equal access to quality health care and prevention

Asia, East Asia, Southeast Asia, Eastern Europe, and

across all populations, and proven effective in-

sub-Saharan Africa (Supplemental Figure 13), and

terventions that reduce mortality and improve out-

prevalence of stroke survivors was highest in Oce-

comes post-stroke.

ania, Southeast Asia, East Asia, and the Middle East/
North Africa regions (Figure 3). These data suggest

HYPERTENSIVE HEART DISEASE. The global preva-

that applying preventive strategies, such as treatment

lence of HHD has risen steadily over the last 3 de-

of elevated blood pressure and cholesterol levels, can

cades, as have the total number of deaths, DALYs,

have major health beneﬁts where stroke burden re-

YLLs, and YLDs due to this disease. In 2019, HHD was

mains high, especially in those regions that did not

the main cause of 1.16 million (95% UI: 0.86 to 1.28

show substantial decline over the past decades (i.e.,

million) deaths and 21.5 million (95% UI: 16.4 to 23.9

Central Asia, Southern sub-Saharan Africa).

million) DALYs annually, with a global prevalence of

Stroke remains the second-leading cause of death,
and stroke burden in terms of DALYs is increasing.

18.6 million (95% UI: 13.5 to 24.9 million) cases
(Supplemental Figure 14A).

Primary stroke prevention strategies are not sufﬁ-

The age-standardized prevalence and YLDs of HHD

ciently effective as currently implemented in many

per 100,000 persons have been constant over time,

countries. Large (15- to 20-fold) geographic variations

and corresponding age-standardized rates of deaths,

in age-standardized stroke DALYs and mortality rates

DALYs,

and moderate (4-fold) geographic variations in age-

mid-2000s

standardized prevalence may be related to the varia-

(Supplemental Figure 14B). The trends for the ab-

tions in stroke risk factors or the quality of and/or

solute

access to preventative care, acute stroke care, and

resemble those for high blood pressure. Taken

stroke rehabilitation across the globe. Global and

together, the increasing global prevalence and rates

national health systems need to focus on new

of HHD can be explained by population growth and

and

and

YLLs
and

declined

have

steadily

leveled

age-standardized

off

until
since

estimates

the
then

closely
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F I G U R E 4 Map of Age-Standardized DALYs Due to Hypertensive Heart Disease in 2019

DALYs ¼ disability-adjusted life years.

aging, but the declining age-standardized rates of

because no such peaks are noted for high blood

adverse outcomes are similar to those for IHD and

pressure or other contributing factors, and it can

stroke and are likely an effect of improved sec-

represent regional differences in disease coding,

ondary prevention.

including that of peripartum cardiomyopathy. In-

The age distributions of DALYs due to HHD are

equalities in access to both primary and secondary

very similar in women and men until age 70 years

prevention are a potential cause of these regional

(Supplemental Figure 15). This contrasts to the age

and sex differences.

distributions for high blood pressure, in which men

The global prevalence of HHD and absolute rates of

are overrepresented at younger ages. The similarities

adverse outcomes are expected to continue to rise

by sex in DALYs calls for an equal attention to the

due to population growth and aging. The age-

clinical prevention and treatment of HHD in women

standardized rates of adverse outcomes due to HHD

and men.

are no longer decreasing, and with continuing global

The highest age-standardized rates of DALYs due

increases in obesity and diabetes, corresponding in-

to HHD are noted in Africa (Figure 4). DALYs due to

creases in left ventricular hypertrophy and other as-

HHD are particularly higher in Central sub-Saharan

pects of HHD are likely. Intensiﬁed global and

Africa, followed by most of Africa except Western

regional efforts to lower blood pressure and control

sub-Saharan

similar

other risk factors are needed, for example with

geographic pattern exists for high blood pressure

Africa,

population-wide reductions in dietary sodium intake.

(with the exception of high rates of DALYs in men

Continued surveillance of inequalities in adverse

from high blood pressure in Central Asia and

outcomes due to high blood pressure are necessary to

Eastern Europe). An overrepresentation of DALYs

inform such efforts.

due to HHD in women can be noted in Central and

CONGENITAL HEART ANOMALIES. A total of 3.12

Eastern

(Supplemental

million (95% UI: 2.40 to 4.11 million) babies were born

Figure 16). The signiﬁcance of this is uncertain

with congenital heart anomalies (CHA) in 2019,

sub-Saharan

and

Oceania.

Africa

A
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representing 2,305.2 per 100,000 live births (95% UI:

The very young age distribution in LMICs and large

1,772.9 to 3,039.2 per 100,000 live births), a total of

burden of YLLs due to CHA should drive a global

13.3 million (95% UI: 11.5 to 15.4 million) people were

mandate for investment in data collection and re-

living with CHA, and CHA was the underlying cause

sources to expand access to infant heart surgery in

of 217,000 deaths (95% UI: 177,000 to 262,000

regions in most need. In low-income countries with

deaths), of which 150,000 deaths (95% UI: 120,000 to

very young populations, the prevalence and mortality

184,000 deaths) were in infants <1 year (Figure 5A).

from RHD parallel lack of access to cardiac surgery

The all-ages rates of DALYs, YLLs, and YLDs for CHA

services for CHA, and pooling resources to care for

in 2019 were 241.6 per 100,000 (95% UI: 196.1 to 292.7

both of these diseases makes a stronger case for in-

per 100,000), 234.0 per 100,000 (95% UI: 189.8 to

vestment in surgical services (that includes both in-

285.7 per 100,000), and 7.6 per 100,000 (95% UI: 3.7

country surgical personnel and nongovernmental or-

to 12.7 per 100,000), respectively (Figure 5B).

ganizations) than for either disease alone.

Between 1990 and 2019, the global CHA birth rate

RHEUMATIC HEART DISEASE. The prevalence of

was largely unchanged, but the all-ages death rate

RHD has been rising steadily since 1990, reaching

due to CHA declined 60.4% (95% UI: –71.9% to

40.5 million (95% UI: 32.1 to 50.1 million) currently

–41.4%) from 7.1 per 100,000 (95% UI: 5.0 to 10.5 per

affected in 2019 (Supplemental Figure 17A). Deaths

100,000) in 1990 to 2.8 per 100,000 (95% UI: 2.3 to 3.4

decreased until 2012 but have stabilized since then

per 100,000) in 2019. Age-standardized prevalence,

and even started increasing since 2017 (306,000 [95%

death, and DALY rates remain lower than all-ages

UI: 259,000 to 340,000] in 2019). DALYs and YLLs

rates in low-income countries because of younger

have slowly decreased to 10.7 million (95% UI: 9.21 to

populations, higher birth rates of CHA, and much less

12.1 million) and 8.68 million (95% UI: 7.43 to 9.77

access to the intervention that is needed to allow for

million), respectively, in 2019, whereas YLDs have

the survival of children born with CHA.

increased

The proportion of all infant deaths caused by CHA

to

1.99

million

(95%

UI:

1.20

to

3.04 million).

increased in all quintiles of the sociodemographic

Age-standardized rates for RHD prevalence have

index (SDI) since 1990 except the highest because

closely tracked with all-age rates, but age-standard-

improvement in CHA mortality has lagged behind

ized mortality has exceeded all-age mortality until the

that of other causes, most notably infectious, respi-

past few years, highlighting the differential mortality

ratory, and diarrheal diseases (16). In low-SDI regions,

risk due to RHD observed in regions with differing age

CHA death rates have declined by 42.1% (95% UI:

structures and levels of development (Supplemental

–61.9% to 12.1%) since 1990, compared with declines

Figure 17B). The narrowing of this differential tells a

of 71.3% (95% UI: –74.7% to –64.6%) in high-SDI

positive story about RHD care, although the domi-

subgroups.

has

nance of China and India in the overall ﬁgures may

limited ability to reduce the burden of CHA after

mask persistent differentials in other high-prevalence

birth; improvements in early diagnosis and access to

countries and regions. The continuing increase in

cardiac surgery are the only solutions.

prevalence cannot be attributed to changes in age

Unlike

other

CVDs,

prevention

The total number of global CHA births remained

structure but likely reﬂects increased global aware-

steady, global CHA deaths decreased by 42.7% (95%

ness, the increasing availability of echocardiography

UI: –59.3% to –15.2%), and the global number of

for case deﬁnition, improved survival in some places,

individuals living with CHA increased by 28.2%

and the chronic nature of RHD.

(95% UI: 26.3% to 30.1%). There were increases in

Globally, the prevalence of RHD is estimated to

the 15- to 49-year and the 50- to 69-year age

peak between 20 and 29 years, remain relatively sta-

groups, in which the number of individuals living

ble until 40 years, and then begin a steady decline,

with CHA grew by 41.6% (95% UI: 40.0% to 43.2%)

likely reﬂecting decreasing survival at older ages. Sex

and 117.3% (95% UI: 114.7% to 120.0%) to 4.21

distribution is equal until the age of 15 years, after

million (95% UI: 3.67 to 4.76 million) and 1.31

which women bear a higher burden in terms of

million (95% UI: 1.13 to 1.51 million), respectively,

prevalence across nearly all world regions. Higher

reﬂecting a cohort effect from the time of birth.

rates of RHD in post-pubertal females are well

Most of the prevalence increase occurred outside of

described, but incompletely understood, and may

high-income countries (HICs) and was due to im-

reﬂect the interaction of biological, social, and envi-

provements in survival and population growth.

ronmental risk factors.

Health systems will be increasingly burdened with
adolescents

and

adults

needing

congenital heart conditions.

care

for

their

RHD burden continues to show substantial global
heterogeneity (Supplemental Figure 18). The highest
age-standardized DALY rates are seen in Oceania and
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F I G U R E 5 Total Numbers and Rates of Congenital Heart Anomalies
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(A) Total number and number among children younger than 1 year of DALYs, deaths, prevalent cases, YLDs, and YLLs due to congenital heart
anomalies, 1990 to 2019. Shaded regions represent 95% uncertainty intervals. (B) Age-standardized and all-ages DALY, death, prevalence,
YLD, and YLL rates of congenital heart anomalies, 1990 to 2019. Shaded regions represent 95% uncertainty intervals. Abbreviations as in
Figure 1.
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F I G U R E 6 Map of Age-Standardized DALYs Due to Rheumatic Heart Disease in 2019

DALYs ¼ disability-adjusted life years.

South Asia (627.4 per 100,000 [95% UI: 404.1 to 918.0

The 2018 World Health Assembly Global RHD Reso-

per 100,000] and 348.5 per 100,000 [95% UI: 272.4 to

lution recommends to increase multisector invest-

412.2 per 100,000], respectively) with the lowest in

ment in primary health care, improve sanitation and

the

100,000).

housing, infrastructure, secure medication supply

Furthermore, although some regions have shown

chains, evidence-based RHD screening, prevention

large declines between 1990 and 2019 (Eastern and

and management, and tertiary capacity to care for

Central Europe, East Asia, Central Latin America,

patients at the severe end of the RHD spectrum. RHD

high-income Asia Paciﬁc, and North Africa and the

burden could be greatly decreased with an effective

Middle East), there are also regions with only modest

group A streptococcal vaccine, with several promising

improvements

little

candidates currently in development (17). Future data

improvement has been seen (Oceania, South Asia, the

collection is needed at subnational levels to identify

Caribbean, and sub-Saharan Africa). There is also

and monitor populations with ongoing high RHD

substantial within-region national and subnational

burdens.

highest-income

and

regions

regions

(<25

per

where

very

variability in RHD DALYs, some examples of which
include substantially higher RHD DALYs in Guyana

CARDIOMYOPATHY AND MYOCARDITIS. DALYs due

and Haiti compared to the rest of Latin America

to cardiomyopathy and myocarditis have increased

and the Caribbean and the heterogeneity seen in

from 7.06 million (95% UI: 6.30 to 8.63 million) to 9.14

the subnational data on RHD DALYs from India

million (95% UI: 7.86 to 10.0 million) over the past 30

(Figure 6).

years, a pattern that is also seen in the rise of deaths

RHD burden is highest among the world’s most

from 238,000 (95% UI: 212,000 to 257,000) to 340,000

disadvantaged populations. The most marginalized

(95%

and poorest populations regionally, nationally, and at

Figure 19A). However, over the same period, the

a

of

age-standardized rate of death has decreased from

improvement and continue to die early from RHD.

8.0 per 100,000 (95% UI: 6.4 to 8.6 per 100,000) to 5.6

subnational

level

are

not showing

signs

UI:

285,000

to

371,000)

(Supplemental
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per 100,000 (95% UI: 4.5 to 6.3 per 100,000) in men

ranged from 5 to 46 DALYs per 100,000 in South Asia,

and 5.8 per 100,000 (95% UI: 4.4 to 6.4 per 100,000)

East Asia, Andean Latin America, high-income Asia

to 3.3 per 100,000 (95% UI: 2.7 to 3.6 per 100,000) in

Paciﬁc, and Central Latin America to 96 to 147 per

women. The age-standardized morbidity and mor-

100,000 in Oceania, the Caribbean, high-income

tality for men and women in 2019 remains different,

North America, and Western and Eastern sub-

at 6.5 per 100,000 YLDs (95% UI: 4.3 to 9.3 per

Saharan Africa to 230 to 271 per 100,000 in Central

100,000 YLDs) and 4.2 per 100,000 YLDs (95% UI: 2.8

Asia, Eastern Europe, and Southern and Central sub-

to 6.0 per 100,000 YLDs) and 148.9 per 100,000 YLLs

Saharan Africa. These regional variations may be

(95% UI: 120.2 to 168.7 per 100,000 YLLs) and 71.4

explained by a higher prevalence of peripartum car-

per 100,000 YLLs (95% UI: 61.0 to 79.9 per 100,000

diomyopathy in Africa, Chagas disease in Central and

YLLs), respectively.

South America, and alcohol-related cardiomyopathy

The prevalence and related mortality of cardiomyopathy

and

myocarditis

increase

in parts of Central Europe and Russia (20).

throughout

Although the morbidity and mortality rates from

adulthood in both sexes, with a larger proportion of

cardiomyopathies and myocarditis collectively pre-

cases in men than in women. When myocarditis alone

sent a substantial global disease burden in 2019, the

is considered, a similar trend was observed. Referring

regional differences in the burden (Figure 7) suggest

to 2019, in the age between 35 and 39 years,

that public health interventions should be tailored to

when myocarditis can commonly occur (18,19), the

the speciﬁc etiologies of cardiomyopathy to lower

rate of myocarditis is 6.1 per 100,000 (95% UI: 4.2

these rates in the future.

to 8.7 per 100,000) in men and 4.4 per 100,000 (95%
UI: 3.0 to 6.3 per 100,000) in women. Similar ﬁgures

ALCOHOLIC CARDIOMYOPATHY. The global preva-

can be found in the range of ages between 20 and 44

lence of alcoholic cardiomyopathy (AC) estimated by

years.

GBD 2019 was 708,000 cases (95% UI: 545,000 to

The increased prevalence associated with aging is
more

pronounced

(95% UI: 7.0 to 11.9 cases per 100,000) (Supplemental

myocarditis. Approximately a 6-fold higher age-

Figure 21A). Globally, AC was responsible for 71,700

related

was

deaths (95% UI: 60,200 to 82,000 deaths), 2.38

observed in men between 35 and 39 years (10.8 per

million YLLs (95% UI: 2.00 to 2.73 million YLLs), and

100,000 [95% UI: 6.5 to 17.4 per 100,000]) versus

60,100 YLDs (95% UI: 38,500 to 88,300 YLDs). The

those between 80 and 84 years (698.5 per 100,000

total number of DALYs due to AC was 2.44 million

[95% UI: 429.6 to 1064.8 per 100,000]) compared with

(95% UI: 2.05 to 2.78 million). After a rapid increase

myocarditis in men of 35 to 39 years (6.1 per 100,000

from

[95% UI: 4.2 to 8.7 per 100,00]) versus those of 80 to

decreasing from 2005 to 2019. The global prevalence

84 years (63.0 per 100,000 [95% UI: 43.6 to 87.9 per

and YLDs due to AC are increasing.

of

cardiomyopathies
other

than

924,000 cases), approximately 9.1 cases per 100,000

in

increase

in

cardiomyopathy

1999,

DALYs,

deaths,

and

YLLs

started

100,000]). The relatively greater rise of other cardio-

All-age and age-standardized rates of DALYs,

myopathy compared to myocarditis prevalence with

deaths, prevalent cases, YLDs, and YLLs declined

age is constant, from 1990 to 2019.

from 2005 to 2019 (Supplemental Figure 21B). This

Myocarditis-related mortality rate between 35

indicates that the global increase in AC prevalence is

and 39 years was 0.2 per 100,000 (95% UI: 0.2 to

related, in part, to population growth and aging.

0.3 per 100,000) in men compared to 0.1 per

Several countries in East Asia and the Caribbean re-

100,000 (95% UI: 0.1 to 0.2 per 100,000) in women

gions

in 2019. Alternatively, myocarditis resulted in death

age-standardized values for almost all indicators.

in 1 in 72 men (585 deaths per 42,200 incident

Factors that might explain these regional differences

cases) and 1 in 87 (324 deaths per 28,100 incident

remain incompletely understood.

showed

opposite

trends,

with

increasing

cases) women in this age bracket who were diag-

At the global level, substantially more total DALYs

nosed in 2019. Between ages 80 and 84 years, the

due to AC were experienced by men than women.

rate was higher, at 1 death for every 19 incident

DALYs from AC rose rapidly among men beginning

cases of myocarditis in men (1,800 deaths per

from age 25 years, being signiﬁcantly higher in men

34,400 incident cases) and 1 death for every

than

15 incident cases of myocarditis in women (2,260

Figure 22). Women are generally considered more

deaths per 34,900 incident cases).

susceptible to alcohol-induced damages than men,

women

across

all

ages

(Supplemental

Marked regional variations in other cardiomyopa-

which may reﬂect sex-speciﬁc differences in alcohol

thy in age-standardized DALYs in both sexes were

consumption, type, blood level, distribution, or

observed in 2019 (Supplemental Figure 20). These

metabolism. However, the higher level of alcohol
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F I G U R E 7 Map of Age-Standardized DALYs Due to Cardiomyopathy and Myocarditis in 2019

DALYs ¼ disability-adjusted life years.

consumption and the higher frequency of alcohol

emphasis on eliminating alcohol use among people

problems among men could justify the observed

with co-existing CVD is advisable. A deeper under-

higher rate of DALYs.

standing of the exact mechanisms of disease, sus-

Age-standardized DALYs due to AC were higher in

ceptibility to alcohol damage, effective public health

Central Europe as well as in the Caribbean (Cuba),

interventions and treatments for AC, can optimize

followed by Australasia, North America, Central Asia,

preventive measures.

Western

America

AF AND AFL. The total number of DALYs due to AF

(Figure 8). Extremely high rates were seen in Eastern

and AFL increased progressively from 3.79 million

Europe, particularly in Russia and Kyrgyzstan. The

(95% UI: 2.96 to 4.83 million) in 1990 to 8.39 million

lowest levels were observed in sub-Saharan Africa,

(95% UI: 6.69 to 10.5 million) in 2019 (Supplemental

Andean Latin America, and North Africa and the

Figure 23A). GBD 2019 estimated 59.7 million (95%

Middle East. Geographic differences reﬂect drinking

UI: 45.7 to 75.3 million) prevalent cases of AF/AFL in

patterns among regions, for example, rates of binge

2019, about a doubling compared to the prevalent

drinking, as well as social and cultural behaviors,

cases in 1990.

Europe,

and

tropical

Latin

such as abstaining from alcohol.

When standardized for age, prevalence of AF/AFL,

AC represents substantial morbidity and mortality

DALYS, and death rates did not display marked

among young and middle-age people, particularly

changes between 1990 and 2019 (Supplemental

men. The age-standardized DALYs are high in several

Figure 23B). The age-standardized AF/AFL preva-

countries, and the true burden of disease could be

lence rate was 775.9 per 100,000 (95% UI: 592.4 to

underestimated because alcohol consumption is

990.8 per 100,000) in 1990 and 743.5 per 100,000

often underreported (21). Additional support for

(95% UI: 571.2 to 938.3 per 100,000) in 2019. Age-

public education and awareness can help to reduce

standardized rates for DALYs did not change sub-

the harmful use of alcohol. Since alcohol negatively

stantially between 1990, when they were 110.0 per

impacts cardiovascular function, increased clinician

100,000 (95% UI: 87.7 to 139.2 per 100,000), to 2019,
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F I G U R E 8 Map of Age-Standardized DALYs Due to Alcoholic Cardiomyopathy in 2019

DALYs ¼ disability-adjusted life years.

when they were 107.1 per 100,000 (95% UI: 86.2 to

the Caribbean, sub-Saharan Africa, and North Africa

133.7 per 100,000). Similarly, the age-standardized

and the Middle East displayed low rates. However,

death rates per 100,000 were similar in 1990 at 4.3

because of a general lack of data from these regions,

per 100,000 (95% UI: 3.7 to 5.1 per 100,000) and 4.4

more detailed studies should be performed. The

per 100,000 (95% UI: 3.7 to 5.0 per 100,000).

reasons for this signiﬁcant regional variation may

Comparing total numbers with age-standardized

include increased ascertainment in high-income

numbers suggests that global increases in AF/AFL

regions, differential control of risk factors, and ge-

are largely attributable to aging of the population and

netic factors. A detailed comparison of potential

population growth.

differentiating features between highest DALY rate

Globally, under the age of 70 years, more total
DALYs due to AF were experienced by men than

versus lowest DALY rate regions could yield valuable
additional information.

women (Supplemental Figure 24). Between 70 and 74

AF/AFL are the most common arrhythmias and

years, men and women had similar DALYs. However,

continue to make a progressive and substantial

at age 75 years and older, this trend was reversed,

impact on public health at a global level. In most

with

by

regions, prevalence rates are increasing, suggesting

women. These trends were observed in 1990 as well

that more effort is needed to improve prevention

as 2019. These ﬁndings point toward sex-speciﬁc,

and health care for AF/AFL at a global level. Health

age-related targets for the prevention and manage-

systems and countries will need to focus their ef-

ment of AF/AFL.

forts to reverse these trends by aggressive attention

higher

total

DALYs

experienced

Age-standardized DALY rates due to AF/AFL were

to the reduction of risk factors such as hyperten-

highest in high-income North America, Australasia,

sion, diabetes, and obesity; better treatment of in-

Central Asia, and Europe and were observed to be

dividuals with IHD and heart failure; and improved

lowest

access

in

the

high-income

Asia

Paciﬁc

region

(Figure 9). Also, Andean and Central Latin America,

to

prophylaxis.

medications

for

thromboembolism

2997

2998
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F I G U R E 9 Map of Age-Standardized DALYs Due to Atrial Fibrillation and Flutter in 2019

DALYs ¼ disability-adjusted life years.

AORTIC ANEURYSM. The total number of YLLs due

rate in women has been shown to be more rapid,

to aortic aneurysm, including both thoracic and

rupture during surveillance 4 times more likely, and

abdominal types, has increased steadily since 1990,

likelihood of fatal rupture 3 times as high, even after

reaching 3.32 million YLLs (95% UI: 3.11 to 3.52 million

adjustment for age (22–24). For thoracic aortic aneu-

YLLs) and 172,000 deaths (95% UI: 157,000 to 183,000

rysms, women have a lower incidence but are more

deaths) in 2019 (Figure 10A).

likely to have fatal consequences than men (25).

Age-standardized

rates

for

YLLs

and

deaths

Age-standardized YLLs due to aortic aneurysm

declined over this period, indicating that, overall,

were highest in Eastern and Central Europe as well as

global increases in aortic aneurysm have been due to

Southern and Tropical Latin America, with extremely

population growth and aging (Figure 10B). This likely

high levels noted in Montenegro and parts of Brazil

reﬂects improvement in diagnosis and treatment of

(Supplemental Figure 26). The lowest levels were

risk factors.

observed in Andean Latin America, North Africa and

At the global level, men bore a substantially higher

the Middle East, and East Asia, including Mexico,

burden of YLLs due to aortic aneurysm compared with

Iraq, and China. Risk factors, including tobacco use

women. YLLs from aortic aneurysm rose most steeply

and hypertension, as well as access to screening and

in the sixth decade of life for men, peaking by age 70

preventive health care, may partially explain these

years (Supplemental Figure 25). Women younger than

patterns.

age 75 years accounted for less than one-half of YLLs

Aortic aneurysm remains a major public health

due to aortic aneurysm. The gap between men and

issue, with the overall burden in terms of number of

women narrowed with increasing age, with YLLs in

YLLs and deaths increasing globally. Because age-

women overtaking those of men at age 90 years. This

standardized rates for YLLs and death due to aortic

could be explained by the generally longer lifespan of

aneurysm declined from 1990 to 2019, the increase

women compared with men. Despite the lower preva-

may be attributable to population growth and aging.

lence of abdominal aortic aneurysm than men, growth

However, because the risk factors for this disease
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F I G U R E 1 0 Total Numbers and Rates of Aortic Aneurysm
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(A) Total number of deaths and YLLs due to aortic aneurysm, 1990 to 2019. Shaded regions represent 95% uncertainty intervals. (B) Age-standardized and all-ages
death and YLL rates of aortic aneurysm, 1990 to 2019. Shaded regions represent 95% uncertainty intervals. YLLs ¼ years of life lost.

remain common, most national health systems will

NONRHEUMATIC

need to address increasing demand for preventive

CALCIFIC AORTIC VALVE DISEASE. Calciﬁc aortic

VALVULAR

HEART

DISEASE:

care, including low-cost screening modalities for

valve disease (CAVD) occurs commonly among older

abdominal aneurysms in the high-burden regions

adults with a normal trileaﬂet aortic valve and with a

mentioned earlier. The risk factors underlying the

greater frequency among those with a congenital

development of aortic aneurysm are common to

bicuspid aortic valve. CAVD is clinically important

other CVDs, such as IHD. As such, mitigating risk

because severe obstruction causes symptoms and left

factors through, for example, hypertension man-

ventricular dysfunction warranting surgical or trans-

agement and smoking cessation, could reduce the

catheter valve replacement (26). The prevalence of

burden of other diseases in addition to aortic

CAVD increases with age and is >1,000 per 100,000

aneurysm. Combined with effective and accessible

beyond the age of 75 years.

screening technology, such as ultrasound, where

Globally,

both

the

prevalence

and

age-

indicated, the morbidity and mortality due to

standardized prevalence of CAVD have increased

aortic aneurysm can be signiﬁcantly decreased

steadily over the last 3 decades (Supplemental

globally.

Figure

27B).

In

2019,

the

age-standardized

2999

3000
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F I G U R E 1 1 Age-Standardized DALYs Due to Nonrheumatic Calciﬁc Aortic Valve Disease in 2019 by Region
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Age-standardized DALY rate of nonrheumatic calciﬁc aortic valve disease by region and sex with 95% uncertainty intervals, 2019. DALYs ¼ disability-adjusted life years.

prevalence rose to approximately 116.3 cases per

prevalence among men exceeds that among women

100,000 (95% UI: 100.4 to 134.5 cases per 100,000)

to varying degrees in the other regions of the world.

people, from about 45.5 cases per 100,000 (95% UI:

Population-based studies of the prevalence of non-

37.6 to 54.7 cases per 100,000) people in 1990. This

rheumatic valvular heart disease remain rare, and

increase may be attributable to increased prevalence

further research is needed to understand if sex dif-

of atherosclerotic risk factors associated with the

ferences in prevalence are due to differences in dis-

development and progression of CAVD (27). Although

ease burden, health-seeking behavior, or rates of

age-standardized YLDs due to CAVD have increased

diagnosis.

in parallel with prevalence, there has been no sig-

There is substantial heterogeneity among coun-

niﬁcant change in age-standardized DALYs, most

tries in age-standardized prevalence and DALYs due

likely because most of the DALYs due to CAVD accrue

to CAVD (Figure 11). Prevalence is low (<20 per

from YLLs, whereas deaths due to CAVD (and conse-

100,000) in several regions of the world, notably,

quently, age-standardized YLLs) have not increased

sub-Saharan Africa (excluding the south), most of Asia

over the years. The ready availability of aortic valve

(including South and Southeast Asia), North Africa and

replacement in regions of the world where CAVD is

the Middle East, and Oceania. In contrast, age-

most prevalent may be an important check on

standardized prevalence is much higher (>200 per

mortality.

100,000) in Australasia; high-income Asia Paciﬁc and

In HICs, the age-standardized prevalence of CAVD

North America; and Central, Eastern, and Western

is similar among both men and women, while the

Europe. The difference may reﬂect higher prevalence
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of other competing illnesses and lack of testing for

DALYs due to MV disease than men, peaking at age 75

CAVD in LMICs. Despite the low prevalence of CAVD in

to 79 years. Prior studies have found that women with

LMICs, DALYs due to CAVD are disproportionately

severe regurgitation have higher mortality and lower

high, possibly reﬂecting the limited access to timely

surgery rates than men, which may account for some

aortic valve replacement (28).

of the increased DALYs in older women (32).

As populations age, CAVD becomes an increasingly

Age-standardized DALYs due to MV disease were

important cause of morbidity and mortality. The in-

highest for both men and women in Central Europe;

crease in reported prevalence of CAVD may be a

speciﬁcally, high rates were seen in Serbia, Bosnia

consequence of both an increase in the prevalence of

and Herzegovina, and Hungary, with the lowest

risk factors for atherosclerosis and an increased

levels seen in Southeast Asia, East Asia, and Andean

awareness

and

investigation

to

detect

disease.

Latin America (Supplemental Figure 29). Women had

Although major advances have been made in the

higher DALYs than men in most regions except Cen-

treatment of end-stage CAVD, research on ways to

tral Asia, Eastern Europe, Australasia, the Caribbean,

prevent the onset and progression of disease requires

and

additional investments. In the populous regions of

Figure 30).

Western

sub-Saharan

Africa

(Supplemental

the world such as South Asia and Africa, despite the

Degenerative MV disease continues to be a major

low prevalence of CAVD, the absolute number of

threat to public health, and the overall burden in

people with CAVD is large. An improved health care

terms of number of DALYs, deaths, and prevalent

infrastructure and an augmented healthcare work-

cases is increasing globally. Prevention of MV disease

force could provide timely valve interventions for

through reduction in risk factors remains a key public

these patients and thereby reduce related morbidity

health issue. In addition, given an aging population in

and mortality.

many regions, health systems should focus on
improving access to diagnostic imaging (i.e., echo-

NONRHEUMATIC

VALVULAR

HEART

DISEASE:

cardiography) and subspecialty care for close follow-

DEGENERATIVE MITRAL VALVE DISEASE. The major

up. Improved access to surgical and percutaneous

cause of nonrheumatic degenerative mitral valve

interventions is also needed to decrease mortality

(MV) disease is MV prolapse (29,30). Untreated, this

and long-term sequelae and improve quality of life for

can lead to chronic mitral regurgitation, AF, and heart

those with MV disease (33).

failure (31). The total number of DALYs due to
degenerative MV disease has increased since 1990

ENDOCARDITIS. The total number of DALYs due to

and is responsible for 883,000 DALYs (95% UI:

endocarditis has risen steadily since 1990, reaching

754,000 to 1,090,000 DALYs) and 34,200 deaths (95%

1.72 million (95% UI: 1.36 to 1.94 million) DALYs and

UI: 28,300 to 43,300 deaths) in 2019 (Supplemental

66,300 deaths (95% UI: 46,200 to 75,900 deaths) in

Figure 28A). GBD 2019 estimated 24.2 million (95%

2019 (Figure 13A). GBD 2019 estimated 1.09 million

UI: 23.1 to 25.4 million) prevalent cases of degenera-

(95% UI: 0.913 to 1.30 million) incident cases of

tive MV disease in 2019.

endocarditis in 2019.

Age-standardized rates for DALYs, deaths, and

Age-standardized rates show an increase in inci-

prevalent cases of degenerative MV disease declined

dence, from 9.9 per 100,000 (95% UI: 8.2 to 11.8 per

over this time period, suggesting that the global in-

100,000) to 13.8 per 100,000 (95% UI: 11.6 to 16.3 per

creases in MV disease have been due to population

100,000), as well as deaths, from 0.7 per 100,000

growth and aging (Supplemental Figure 28B). The

(95% UI: 0.6 to 0.9 per 100,000) to 0.9 per 100,000

regions

age-

(95% UI: 0.6 to 1.0 per 100,000) (Figure 13B). Although

standardized DALYs between 1990 and 2019 are

there has been a slight increase in the DALYs, YLLs,

high-income Asia Paciﬁc, North Africa and the Middle

and YLDs caused by endocarditis across all ages, once

East, and Australasia. However, for some regions—for

standardized for age structure and growth, these

example, in Eastern Europe and Central Asia—age-

metrics are largely static between 1990 and 2019. The

standardized rates have not declined.

increase in death may be explained by an increasing

with

the

largest

reductions

in

At the global level, substantially more total DALYs

proportion of endocarditis caused by virulent organ-

due to MV disease were experienced by women than

isms such as staphylococci or complex infection in

men. For almost all age groups, MV disease DALYs

patients not ﬁt for surgical intervention.

were higher in women than men (Figure 12). Globally,

At the global level, more total DALYs due to

women and men had similar DALYs in the 40- to 44-

endocarditis were experienced by men than women

year age groups, but the levels diverged after age 65

in 2019 (973,000 DALYs [95% UI: 736,000 to 1,120,000

years, when women had more than one-third more

DALYs] versus 751,000 DALYs [95% UI: 537,000 to

3001
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F I G U R E 1 2 DALYs Due to Nonrheumatic Degenerative Mitral Valve Disease in 2019 by Age
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Number of DALYs due to nonrheumatic degenerative mitral valve disease by age and sex with 95% uncertainty intervals, 2019. Ages younger than 15 years
were removed from the ﬁgure because they are not modeled for this cause. DALYs ¼ disability-adjusted life years.

871,000 DALYs]). DALYs from endocarditis rose

large part, areas with high age-standardized DALY

rapidly for both sexes from birth and reached a peak

rates for endocarditis mirror those areas with a high

at age 55 to 59 years for men and age 65 to 69 years

prevalence of RHD, for example, in Oceania, South-

for women (Supplemental Figure 31). Women ages

east Asia, and sub-Saharan Africa.

75 years and older had more DALYs due to endocarditis than men in the same age group.
There is wide variation in the regional age-

The epidemiology of endocarditis, including predisposing conditions, is heterogeneous. Therefore, it is
not surprising that the endocarditis-associated YLDs

endocarditis

and DALYs vary considerably by location. Both the

(Supplemental Figures 32 and 33). In 2019, the highest

endocarditis-associated YLDs and DALYs increased in

rates were seen in Oceania, with 44.9 DALYs per

76.2% and 52.4% of locations, respectively. Staphylo-

100,000 (95% UI: 30.7 to 60.7 DALYs per 100,000)

coccus aureus has become the predominant endo-

(across men and women), followed by Southern Latin

carditis pathogen in many areas of the world and is

America (40.1 DALYs per 100,000 [95% UI: 32.7 to

extremely virulent and a well-recognized marker of

49.6 DALYs per 100,000]) and Southeast Asia (38.6

worse outcomes (34). As a result, mounting human and

DALYs per 100,000 [95% UI: 31.6 to 53.8 DALYs per

health care burdens mandate that an individualized

100,000]). There were also high rates in Eastern

approach be developed for each location to better un-

Europe (especially in men), the Caribbean, Tropical

derstand the unique epidemiology of endocarditis so

Latin America, and Africa. The lowest DALYs for

that efforts can be focused on management and pre-

endocarditis were seen in Central and East Asia. In

vention of this life-threatening condition.

standardized

DALY

rate

due

to
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F I G U R E 1 3 Total Numbers and Rates of Endocarditis
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(A) Total number of DALYs, deaths, incident cases, YLDs, and YLLs due to endocarditis, 1990 to 2019. Shaded regions represent 95%
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F I G U R E 1 4 Map of Age-Standardized DALYs Due to Peripheral Artery Disease in 2019

DALYs ¼ disability-adjusted life years.

PERIPHERAL ARTERY DISEASE. The global numbers

increased throughout the

of prevalent cases and deaths due to PAD have risen

Numbers and rates of cases were higher in women

consistently each year since 1990, resulting in a 2-fold

than men at all ages. Deaths and DALYs showed in-

increase to 113 million cases (95% UI: 99.2 to 128

creases with age comparable to prevalence except

million cases) and 74,100 deaths (95% UI: 41,200 to

that deaths and DALYs were higher in men than

128,000 deaths) in 2019 (Supplemental Figure 34A).

women up to very old age.

whole age

spectrum.

Comparable trends in DALYs, YLLs, and YLDs have

The numbers of prevalent cases increased in both

resulted in 1.54 million (95% UI: 1.01 to 2.37 million),

men and women at all ages by up to 2-fold since 1990,

1.04 million (95% UI: 0.604 to 1.78 million), and

but age-standardized prevalence rates were slightly

501,000 (95% UI: 235,000 to 898,000) respec-

lower in 2019 than in 1990. Numbers of deaths and

tively in 2019.

DALYs were higher in 2019 compared to 1990 in both

In keeping with the increase in numbers of preva-

men and women at all ages, but over the same period,

lent cases, deaths, DALYS, YLLs, and YLDs, rates per

age-standardized death rates remained much the

100,000 persons of all ages increased between 1990

same, and DALY rates fell slightly.

and 2019 (Supplemental Figure 34B). The trends in

Age-standardized DALY rates varied by world re-

age-standardized rates of deaths and YLLs were ﬂat

gion in 2019 (Figure 14). Higher rates (>25 per 100,000

from 1990 to 2019, and prevalence, YLDs, and DALYs

persons) were found in both men and women in

declined slightly. Overall, the PAD prevalence in-

Europe (western, central, and eastern), North Amer-

crease reﬂects population growth rather than a major

ica, Australasia, the Caribbean, and sub-Saharan Af-

change in age-speciﬁc incidence. In both 1990 and

rica (central, eastern, and southern) (Supplemental

2019, cross-sectional analyses show that the numbers

Figure 35). Especially high rates occurred in men in

of prevalent cases increased with age in both men and

Eastern Europe and areas of sub-Saharan Africa.

women up to 70 years of age and prevalence rates

Lowest DALY rates were found in Asia, Andean

Roth et al.

JACC VOL. 76, NO. 25, 2020
DECEMBER 22, 2020:2982–3021

Global Burden of Cardiovascular Diseases

countries, West and North Africa and the Middle East.

attributed to population growth and aging. However,

The pattern was similar in men and women, with

in some regions—for example, Oceania—the age-

most regions showing higher rates in men, but in re-

standardized rates of DALYs, deaths, YLDs, and

gions with low overall rates, the sex differences were

YLLs increased between 1990 and 2019.

small. The burden of PAD is increasing not only in

Globally, DALYs due to high SBP in 2019 were

developed HICs but also in LMICs, where concomitant

higher among men compared with women from ages

risk

15 to 19 through 70 to 74 years, but higher among

factors

such

as

diabetes

and

obesity

are

increasing.

women compared to men in those 80 to 84 years or

Despite decreases in PAD age-standardized preva-

older (Figure 15). Age-standardized DALYs were

lence, deaths, DALYs, YLDs, and YLLs, overall rates

higher among men compared with women in all re-

have increased because of worldwide increases in life

gions of the world (Supplemental Figure 37).

expectancy. High DALY rates of PAD in Eastern

In 2019, there was an approximately 8-fold varia-

Europe and parts of Africa, particularly in men,

tion

require investigation. PAD is highly prevalent and is

attributed to high SBP (Supplemental Figure 38).

both underrecognized and inadequately studied.

Rates of DALYs were lowest for both women and men

across

regions

in

age-standardized

DALYs

in the high-income Asia Paciﬁc region and highest in

MODIFIABLE RISK FACTORS

Central Asia. Marked variation was also noted for
rates of death, YLLs, and YLDs. The highest age-

HIGH SYSTOLIC BLOOD PRESSURE. With aging of

standardized rates of death and YLLs were noted in

the population and population growth, the number of

Central Asia and Eastern Europe among men and

adults worldwide affected by high systolic blood

in Central Asia, North Africa and the Middle East, and

pressure (SBP) increased from 2.18 billion (95% UI:

Central sub-Saharan Africa among women. The

95% UI: 2.11 to 2.26 billion) to 4.06 billion (95% UI:

highest rate of YLDs was noted in Central Asia, Cen-

3.96 to 4.15 billion) from 1990 to 2019 (Supplemental

tral Europe, and Southeast Asia for men and in North

Table 1). High SBP is deﬁned by GBD 2019 according

Africa and the Middle East, East Asia, and Southeast

to

Asia for women.

a

theoretical

minimum

risk

exposure

level

(TMREL) of $110 to 115 mm Hg, which is the level of

High SBP is a major public health challenge,

exposure that minimizes risk at the population level.

affecting approximately 9 of 10 adults worldwide,

In 2019, there were 828 million (95% UI: 768 to 888

and is associated with high rates of DALYs, death,

million) adults with SBP >140 mm Hg, a common

YLDs, and YLLs. High SBP and its adverse health

threshold for treatment with pharmacotherapies. The

consequences can be prevented by eating a heart-

prevalence of adults worldwide with high SBP

healthy diet that includes <1 teaspoon of salt per

increased from 84,481.1 per 100,000 persons (95% UI:

day and adequate potassium from fruits and vege-

81,641.5 to 87,579.2 per 100,000 persons) in 1990 to

tables, maintaining a normal weight, increasing

88,971.1 per 100,000 persons (95% UI: 86,950.0 to

physical activity, and avoiding unhealthy alcohol

91,028.8 per 100,000 persons) in 2019.

intake (35).

From 1990 to 2019, the total number of DALYs due

HIGH FASTING PLASMA GLUCOSE. There are large

to high SBP increased from 154 million (95% UI: 139 to

differences between and within countries in the

169 million) to 235 million (95% UI: 211 to 261 million)

burden of high fasting plasma glucose, deﬁned as

(Supplemental Figure 36A). Additionally, between

above the TMREL of 4.8 to 5.4 mmol/l. The ﬁndings

1990 and 2019, the number of deaths (6.79 million

showed

[95% UI: 6.07 to 7.50 million] to 10.8 million [95% UI:

mortality rates from high fasting plasma glucose and

9.51 to 12.1 million]), YLDs (10.1 million [95% UI: 7.30

signiﬁcant increases in age-standardized YLDs be-

to 13.1 million] to 21.2 million [95% UI: 15.2 to 27.2

tween 1990 and 2019. Age-standardized mortality due

million]), and YLLs (144 million [95% UI: 129 to 158

to high fasting plasma glucose actually increased

million] to 214 million [95% UI: 191 to 237 million])

from 1990 to 2005, with a downward trend thereafter.

attributed

to

high

age-standardized

Between 1990 and 2019, a total of 134 million (95%
UI: 107 to 171 million) deaths due to high fasting

attributed to high SBP declined from 1990 to 2019,

plasma glucose were recorded globally. The number

whereas the age-standardized rate of YLDs did not

of deaths increased from 2.91 million (95% UI: 2.34 to

change

3.75 million) in 1990 to 6.50 million (95% UI: 5.11 to

this

The

in

standardized rates of DALYs, deaths, and YLLs

over

increased.

improvement

age-

substantially

SBP

little

time

period

(Supplemental Figure 36B). These data indicate that

8.36

the increases in total number of disease events can be

standardized mortality rate due to high fasting

million)

in

2019

(Figure

16A).

The

age-
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F I G U R E 1 5 DALYs Due to High Systolic Blood Pressure in 2019 by Age
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the ﬁgure because they are not modeled for this risk. DALYs ¼ disability-adjusted life years.

plasma glucose increased between 1990 and 2005

Age-standardized DALYs due to high fasting

from 84.2 per 100,000 deaths (95% UI: 65.9 to 111.1

plasma glucose were higher in Oceania, followed by

per 100,000 deaths) to 89.2 per 100,000 deaths (95%

Central Asia (Supplemental Figure 40). There were

UI: 70.2 to 115.9 per 100,000 deaths) then declined

large variations between countries in high fasting

to 83.0 per 100,000 deaths (95% UI: 64.5 to 107.1 per

plasma glucose DALY burden, with notably high rates

100,000

in Uzbekistan, Afghanistan, Papua New Guinea,

deaths)

in

2019

(Figure

16B).

Age-

standardized DALYs followed the same patterns

Egypt, and Oman (Supplemental Figure 41). The

with a peak in 2005 and then a decline until 2019. In

highest

contrast, age-standardized DALY rates were higher in

observed in Kiribati at 12,255.2 per 100,000 (95% UI:

2019 at 2,104.3 per 100,000 (95% UI: 1,740.7 to 2,520.7

9,799.7 to 15,073.0 per 100,000), and the highest age-

per 100,000) than in 1990 at 1,959.6 per 100,000 (95%

standardized death rates were also observed in

UI: 1,638.7 to 2,362.4 per 100,000). Of course, this is

Kiribati at 435.4 per 100,000 (95% UI: 347.0 to 540.5

the result of a sharp increase in age-standardized

per 100,000). Large variations were also observed

YLDs from 1990 to 2019. Men had higher DALY

within countries. For example, the age-standardized

age-standardized

DALYs

in

2019

were

burden than women throughout the study period

DALY rate varied in Brazil from 1,571.8 per 100,000

until the age of 80 years, after which women had a

(95% UI: 1,293.6 to 1,909.1 per 100,000) in Minas

higher number of DALYs (Supplemental Figure 39).

Gerais to 3,286.5 per 100,000 (95% UI: 2,735.5 to

DALYs due to high fasting plasma glucose increased

3,907.3 per 100,000) in Alagoas, a 70.6% difference in

with age, peaked at 70 years, and then declined.

the country.
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F I G U R E 1 6 Total Numbers and Rates of High Fasting Plasma Glucose
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(A) Total number of DALYs, deaths, YLDs, and YLLs due to high fasting plasma glucose, 1990 to 2019. Shaded regions represent 95% uncertainty intervals. (B) Age-standardized and all-ages DALY, death, YLD, and YLL rates of high fasting plasma glucose, 1990 to 2019. Shaded regions represent 95%
uncertainty intervals. Abbreviations as in Figure 1.
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plasma

Age-standardized DALYs due to high LDL choles-

glucose level help track the global rise in diabetes.

terol were highest in Eastern Europe, North Africa

GBD 2019 showed low rates of physical activity (LPA)

and the Middle East, Oceania, and Central Asia

These

population-based

estimates

of

and poor diet in many countries. Both are major risk

(Supplemental Figure 44). The lowest levels are pre-

factors for high fasting plasma glucose and have led

sent in high-income Asia Paciﬁc, Australasia, Western

to caloric imbalance and higher rates of obesity,

Europe, and Andean Latin America and, by country,

which has rapidly increased globally since 1990 and

in the Republic of Korea, Japan, Rwanda, France,

affects most geographic areas. There is a need to

Israel, and Spain (Figure 17). Potential explanations

develop and implement both public health policies

for these differences in regional patterns include the

and clinical programs to reduce health disparities and

correspondingly LPA, increased high body mass index

disease burden due to diabetes.

(BMI), dietary patterns, and increased tobacco use in

HIGH LOW-DENSITY LIPOPROTEIN CHOLESTEROL.

the same regions and countries.

The total number of DALYs due to high low-density

High LDL cholesterol remains a major threat to

lipoprotein (LDL) cholesterol, deﬁned by a TMREL

public health, and the overall burden in terms of

of 0.7 to 1.3 mmol/l, has risen steadily since 1990,

number of DALYs, deaths, YLDs, and YLLs is

reaching 98.6 million (95% UI: 80.3 to 119 million)

increasing globally. In some locations, the risk

DALYs and 4.40 million (95% UI: 3.30 to 5.65 million)

associated with high LDL cholesterol is especially

deaths in 2019 (Supplemental Figure 42A). Over the

high and deserves immediate public health atten-

same period, the YLDs and YLLs rose to 5.71 million

tion. Health systems and countries may need to

(95% UI: 3.68 to 8.27 million) and 92.9 million (95%

focus on new approaches that can reverse these

UI: 75.6 to 111 million), respectively. This indicates

trends. These might include improved government

that the direction of the global trend for high LDL

policies on diet and tobacco, school physical activity

is increasing.

programs, and, when needed, the use of lipid-

Over the study period, the global all-age rates for

lowering therapy in keeping with contemporary

DALYs, deaths, and YLLs remained relatively static

guidelines in which statins are the ﬁrst choice. More

and increased for YLDs (Supplemental Figure 42B).

global

During this time, the age-standardized rates for the

cholesterol–related knowledge and therapeutic gaps

same measures all declined. This difference between

is needed to address this persistent global health

all-age rates and age-standardized rates suggests that

threat.

investment

in

research

to

address

LDL

although the global burden of LDL-related disease

HIGH BMI. Obesity, deﬁned by elevated BMI ($30 kg/

remains unacceptably high, on average, the observed

m 2), has reached epidemic levels worldwide. Elevated

increases in the burden of DALYs in locations like

BMI worsens most of the CVD risk factors, including

China and India have been driven primarily by pop-

adverse effects on blood pressure, blood sugar, lipids,

ulation growth and aging. This trend is important for

and inﬂammation and has adverse effects on cardiac

global health because it implies that there has been at

structure and function. Not surprisingly, hyperten-

least modest progress in reducing the burden of LDL-

sion, coronary heart disease, heart failure, and AF are

related disease globally. Age-standardized DALY rates

increased with obesity (36).

attributable to elevated LDL cholesterol, however, are
estimated

to

be

increasing

in

some

locations,

including Pakistan and Saudi Arabia.

Globally, 5.02 million (95% UI: 3.22 to 7.11 million)
deaths and 160 million (95% UI: 106 to 219 million)
DALYs

were

attributed

to

high

BMI

in

2019

At the global level, signiﬁcantly more total DALYs

(Figure 18A). High BMI, deﬁned as above a TMREL of

from elevated LDL were experienced by men than

20 to 25 kg/m 2 for adults and above normal weight for

women. LDL-related DALYs increased rapidly for men

children, contributed to more YLLs (119 million [95%

beginning at age 30 years (Supplemental Figure 43).

UI: 79.6 to 164 million]) than YLDs (40.9 million [95%

Men ages 40 to 44 years had as many DALYs due to

UI: 24.5 to 60.9 million]) in 2019. Globally, between

LDL as women ages 60 to 64 and 80 to 84 years and

1990 and 2019, the absolute numbers of deaths

more than women in all other age groups. In aging

attributable to high BMI increased (2.20 million [95%

post-menopausal women, the LDL cholesterol levels

UI: 1.21 to 3.43 million] to 5.02 million [95% UI: 3.22 to

are comparable to those of men of similar age. The

7.11 million]), as did DALYs (67.3 million [95% UI: 38.0

difference in DALYs by sex and age suggests that the

to 104 million] to 160 million [95% UI: 106 to 219

burden of premature LDL-related disease in men

million]), YLDs (12.9 million [95% UI: 6.9 to 21.0

younger than 65 years may need focused public

million]

health attention.

60.9 million]), and YLLs (54.4 million [95% UI: 30.2 to

to

40.9

million

[95%

UI:

24.5

to
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F I G U R E 1 7 Map of Age-Standardized DALYs Due to High LDL Cholesterol in 2019

DALYs ¼ disability-adjusted life years; LDL ¼ low-density lipoprotein.

84.4 million] to 119 million [95% UI: 79.6 to 164
million]).

Age-standardized DALY rates due to high BMI are
highest in Oceania, Central Asia, North Africa and the

After standardization for population growth and

Middle East, Southern sub-Saharan Africa, Eastern

aging, rates of deaths attributable to high BMI have

Europe, Central Latin America, the Caribbean, and

increased only modestly from 1990 to 2019 (4.9% in-

Central Europe (Supplemental Figure 46). Among

crease [95% UI: –7.3% to 24.6%]), DALYs (18.0% [95%

countries, Japan has the lowest and Kiribati the

UI: 2.2% to 42.3%]), and YLLs (8.3% [95% UI: –6.6% to

highest

31.2%]), suggesting that population growth and aging

(Supplemental Figure 47). The global ﬁndings are

of the population have contributed substantially to

generally similar between men and women in most

the global trends in obesity-associated burden of

regions, but age-standardized DALYs are notably

disease (Figure 18B). YLDs have increased more

higher for men in Central Asia and Central and

sharply (60.2% [95% UI: 41.3% to 90.2%]) from 1990

Eastern Europe.

age-standardized

DALYs

in

the

world

to 2019. Since population growth and aging from 1990

Great efforts are needed to promote the prevention

account for much of the absolute increases attribut-

of obesity and its progression to more severe forms

able to high BMI, the focus may need to be on stra-

(36). A multifactorial approach is required to promote

tegies targeting prevention of weight gain at younger

improving dietary quality, especially reductions in

ages to decrease the burden of all measures, including

simple sugars, complex carbohydrates, and total cal-

YLDs.

ories. Community prevention programs, like the

Global DALYs attributable to high BMI are highest

Diabetes Prevention Program, duplicated in many

between ages 45 and 75 years and are slightly higher

programs (37), are needed (36). Optimizing efforts to

for men at younger and middle ages and for women at

promote physical activity and exercise training are

older ages (Supplemental Figure 45).

needed, as well as reductions in sedentary behavior
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F I G U R E 1 8 Total Numbers and Rates of High Body Mass Index
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(A) Total number of DALYs, deaths, YLDs, and YLLs due to high body mass index, 1990 to 2019. Shaded regions represent 95% uncertainty intervals.
(B) Age-standardized and all-ages DALY, death, YLD, and YLL rates of high body mass index, 1990 to 2019. Shaded regions represent 95% uncertainty
intervals. Abbreviations as in Figure 1.
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and

(Figure 19). Men in Central Latin America have among

workplaces more suitable to allow for these healthier

communities,

the highest age-standardized DALYs at 2,091.2 per

lifestyle behaviors. Potential governmental involve-

100,000 people (95% UI: 1,791.6 to 2,424.8 per

ment, such as mandating caloric/nutrition menu la-

100,000 people), double the global rate and 60%

beling and regulation of food ingredients, as well as

higher than in 1990 (Supplemental Figure 52), which

controlling advertisements and certain forms of

represents an epidemic of CKD of unknown origin

beverage and food item taxation, etc., could be

that appears to be common in coastal lowlands, with

instituted. Governmental intervention was very suc-

repeated heat stress, pesticide, and heavy metal

cessful decades ago in the North Karelia Project in

exposure implicated as potential causes (39).

Finland (36,38), and potentially, similar efforts could

CKD is emerging as a growing global problem, with

be successful for obesity intervention worldwide.

marked growth related to the aging population. Age-

Research is needed to identify effective methods of

standardized DALYs for IKF have declined by only

health promotion that will reduce obesity and align

7.7%, compared to 39.3% for all risk factors, and they

all allied health professions toward this important

increased in Central and Andean Latin America, the

goal (36).

Caribbean, Central and Southeast Asia, Oceania, and
Southern sub-Saharan Africa. Much of CKD remains

IMPAIRED KIDNEY FUNCTION. GBD 2019 estimates

undiagnosed and undertreated. Governments, health

use the term chronic kidney disease (CKD) to refer to

systems, physicians, and patient attention are needed

the morbidity and mortality that can be directly

to improve the diagnosis of CKD by measuring pro-

attributed to all stages of CKD and the term impaired

teinuria and estimated glomerular ﬁltration rate.

kidney function (IKF) to capture the additional risk of

There is also a need for earlier markers of kidney

CKD from other associated conditions such as CVD

injury. Diabetes and hypertension are leading factors

and gout. The DALYs due to IKF nearly doubled from

for

1990 to 2019, reaching 76.5 million (95% UI: 67.8 to

Improving their prevention and control will reduce

86.3 million) DALYs and 3.16 million (95% UI: 2.72 to

the burden of CKD. Therapeutic options for CKD are

CKD,

its

progression,

and

associated

risk.

3.62 million) deaths globally in 2019 (Supplemental

increasing

Figure 48A). The estimated global prevalence of

angiotensin system blockade in proteinuria and

CKD is 9,011.9 per 100,000 (95% UI: 8,401.3 to 9,577.8

possibly sodium-glucose cotransporter-2 inhibitors

per 100,000) (697 million [95% UI: 650 to 741 million]

and mineralocorticoid receptor antagonists. Trials are

people), 41.1% (95% UI: 38.9% to 43.4%) higher than

underway to test prevention of kidney events in pa-

in 1990 due to aging (Supplemental Figures 49A

tients with CKD without diabetes. A combination of

and 49B).

population-based

Age-standardized DALYs due to IKF declined

increased

with

CKD

the

proven

public

beneﬁts

health

recognition

and

of

renin-

measures

for

awareness

and

slightly from 1,024.1 DALYs per 100,000 people (95%

improved therapies to reduce risk is needed to reduce

UI: 898.4 to 1,154.8 DALYs per 100,000 people) to

the burden of CKD.

945.3 DALYs per 100,000 people (95% UI: 836.3 to
1,066.8 DALYs per 100,000 people) from 1990 to 2019

AMBIENT AND HOUSEHOLD AIR POLLUTION. Air

(Supplemental Figure 48B). This 7.7% (95% UI: –12.9%

pollution is the leading environmental risk factor for

to –2.4%) decline in DALYs lags behind the 39.3%

global health and the fourth largest risk factor for

(95% UI: –43.5% to –34.9%) decline in DALYs for all

global mortality. Two main forms of air pollution

risk factors combined. The age-standardized rate per

quantiﬁed in GBD 2019 contribute substantially to the

100,000 people for YLDs from IKF increased from

burden of CVD: ambient particulate matter with an

115.9 (95% UI: 84.7 to 150.5) to 139.4 (95% UI: 101.8 to

aerodynamic diameter smaller than 2.5 m m (PM2.5)

181.8) from 1990 to 2019. Growth and aging of the

and household air pollution (HAP) from the use of

global population resulted in an increase in all un-

solid fuels for cooking. In 2019, CVD accounted for

adjusted disease burden measures for IKF.

51.5% and 30.5% of the total DALYS attributable to

CKD and its consequences generally rise markedly

PM2.5 and HAP, respectively.

with age and are higher among men than women, but

Despite substantial reductions in ambient PM 2.5

trends over time were similar across age and sex

concentrations in North America and Europe, levels

groups (Supplemental Figures 50 and 51).

remain high throughout most of the world (40).

Geographically, the highest age-standardized rates

Global annual average population-weighted PM2.5

of DALYs due to IKF are now seen in Central Latin

levels increased slightly from 40.8 mg/m 3 in 1990 to

America, Central Asia, the Caribbean, North Africa

42.6 m g/m 3 in 2019. However, the global disease

and the Middle East, Oceania, and Southeast Asia

burden attributable to ambient PM 2.5 increased from

3011

3012
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F I G U R E 1 9 Map of Age-Standardized DALYs Due to Impaired Kidney Function in 2019

DALYs ¼ disability-adjusted life years.

70.5 million (95% UI: 47.3 to 98.9 million) DALYs and

attributable to HAP have also declined sharply,

2.05 million (95% UI: 1.45 to 2.74 million) deaths in

indicating

1990 to 118 million (95% UI: 95.9 to 138 million)

(Supplemental

DALYs and 4.14 million (95% UI: 3.45 to 4.80 million)

standardized rates of DALYs attributable to HAP

deaths,

remain high throughout much of sub-Saharan Africa,

respectively,

in

2019

(Supplemental

the

impact

of

Figure

54B).

exposure

reduction

However,

age-

Figure 53A). Age-standardized rates for DALYs and

which

deaths attributable to PM 2.5 have remained relatively

improved access to clean household energy sources

constant between 1990 and 2019, indicating that, on

seen in India, China, and much of Southeast Asia

average, global increases in attributable disease have

(Supplemental Figure 55). The highest rates of

been due to population growth and aging, especially

DALYs for HAP were in Oceania; Eastern, Western

in locations with high exposures (Supplemental

and Central sub-Saharan Africa; and South Asia,

Figure 53B). Age-standardized DALYs attributable to

driven by differences in exposure.

has

yet

to

experience

the

beneﬁts

of

PM 2.5 were higher than the global mean in East,

DALYs attributable to PM 2.5 and HAP were higher

Central, and South Asia; North Africa and the Middle

in men, driven by sex differences in rates of the dis-

East; and Southern and Western sub-Saharan Africa

eases

(Figure 20).

Figures 56 and 57). These sex differences were less

affected

by

air

pollution

(Supplemental

In contrast to ambient PM 2.5, the burden attrib-

pronounced for HAP given that women tend to be

utable to HAP decreased sharply from 208 million

more highly exposed. DALYs attributable to HAP had

(95% UI: 162 to 259 million) DALYs and 4.36 million

the largest impacts in infancy and early childhood,

(95% UI: 3.33 to 5.40 million) deaths in 1990 to 91.5

whereas for PM2.5, it was between ages 30 and 90

million (95% UI: 67.0 to 119 million) DALYs and 2.31

years.

million (95% UI: 1.63 to 3.12 million) deaths in 2019

Increased attention to air pollution as a CVD risk

(Supplemental Figure 54A). Trends for both all-age

factor is warranted and will require concerted ac-

and

tion and collaboration between government health

age-standardized

DALYs

and

death

rates
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F I G U R E 2 0 Map of Age-Standardized DALYs Due to Ambient Particulate Matter Pollution in 2019

DALYs ¼ disability-adjusted life years.

and

especially

[95% UI: 180 to 209 million]) far exceeded the number

relevant given high levels of exposure in many

environmental

agencies.

This

is

of attributable YLDs (36.1 million [95% UI: 27.0 to

parts of the world and links between PM2.5 and

46.0 million]), highlighting the outsized effect of to-

health risks at levels substantially below those of

bacco on premature mortality.

current regulatory levels (41). As demonstrated in

Progress in reducing tobacco use and exposure has

North America and Western Europe, air quality

not kept pace with competing demographic forces,

management, coupled with regulation and enforce-

namely, population growth and population aging.

ment, is effective at reducing ambient air pollution

Population growth, particularly in countries with a

and its disease burden (42). Similar approaches

large population of tobacco users, has resulted in an

applied elsewhere, in combination with actions to

increasing number of tobacco-attributable deaths and

reduce emissions of climate-forcing agents will be

DALYs since 1990. When controlling for population

necessary.

in-

growth, decreases in both death and DALY rates are

terventions, such as the use of portable air cleaners,

In

the

observed. However, population aging has resulted in

may be effective (43). Continued reductions in HAP

smaller decreases in all-age rates compared to age-

exposure through programs to improve access to

standardized rates (Figure 21B). With approximately

clean energy sources will lead to both health and

80% of current smokers living in LMICs, these de-

climate beneﬁts (44).

mographic forces will continue to counter progress in

TOBACCO. Tobacco,

interim,

including

personal-level

primary

smoking,

tobacco control for years to come.

secondhand smoke, and use of chewing tobacco,

In 2019, global smoking prevalence among men

accounted for 8.71 million (95% UI: 8.12 to 9.31

was 33.5% (95% UI: 33.1% to 33.9%), and smoking

million) deaths and 230 million (95% UI: 213 to 246

prevalence among women was 6.8% (95% UI: 6.6% to

million) DALYs in 2019 (Figure 21A). Of tobacco-

7.0%). As a result of this difference, 75.4% of smoking

attributable deaths, 36.7% were due to CVD. The

attributable deaths occurred among men. The age

number of YLLs attributable to tobacco (194 million

pattern of tobacco use and exposure, combined with
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F I G U R E 2 1 Total Numbers and Rates of Tobacco
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(A) Total number of DALYs, deaths, YLDs, and YLLs due to tobacco, 1990 to 2019. Shaded regions represent 95% uncertainty intervals.
(B) Age-standardized and all-ages DALY, death, YLD, and YLL rates of tobacco, 1990 to 2019. Shaded regions represent 95% uncertainty intervals.
Abbreviations as in Figure 1.
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the age distribution of associated health outcomes,

million) annual DALYs attributed to dietary risks

results in age-speciﬁc DALYs peaking among men

(Figure 22A). Worldwide, the absolute disease burden

ages 60 to 64 years and among women ages 65 to 69

caused by dietary risks has risen for 30 years,

years (Supplemental Figure 58).

regardless of how measured. Over the same period,

The highest age-standardized tobacco-attributable

age-standardized rates have fallen for most measures,

DALY rates among men were observed in Eastern

indicating the central role of population growth and

Europe, Central Asia, and Oceania (Supplemental

population

Figure 59). Among women, the highest rates were

(Figure 22B). The exception is age-standardized rates

observed in Oceania, high-income North America,

of YLDs caused by dietary risks, which have grown in

and Central Europe. Thirty percent of all current

both absolute and proportional terms.

smokers live in China, and nearly one-third of
tobacco-attributable

deaths

occurred

in

China

in 2019.

aging

on

the

observed

increases

Worldwide, the number of DALYs caused by dietary risks peaks between 55 and 70 years of age for
both men and women, with a large excess of DALYs

With more than 1 billion active tobacco users, the

among men compared to women in every age group

tobacco epidemic remains a central challenge to

to 80 years old (Supplemental Figure 60). Age-

global health. The global disease burden of tobacco

standardized rates of DALYs caused by dietary risks

use continues to increase, attributable in large part

are highest in Central Asia, Oceania, and Eastern

to population growth and falling most heavily on

Europe and lowest in Australasia, HICs of the Asia

LMICs, where the large majority of tobacco users

Paciﬁc, and Western Europe (Supplemental Figures 61

live. Tobacco control measures include increased

and 62). Differences in age-standardized DALY rates

taxes on tobacco, mass media education campaigns,

among populations reﬂect a complex interplay be-

bans

sponsorship,

tween variations in diet quality, levels of exposure to

on

different dietary risks, and access to interventions

on

required

tobacco

marketing

and

prominent

warning

labels

tobacco

products, required environments to be smoke-free,
and ensuring access to and delivery of tobacco

targeting the downstream clinical effects of CVDs.
The detailed effects of many dietary risks are

cessation treatments in health care systems. The

poorly

evidence-based measures are included in the World

hampered by the challenges of accurately quantifying

understood

because

assessments

are

Health Organization’s Framework Convention on

exposures and separating the effects of each risk from

Tobacco Control, a public health treaty that took

those of important covariates. However, the effects of

effect in 2005 and has been ratiﬁed by 182 countries.

dietary risks on CVD remain large whether assessed as

Despite this global commitment, adoption of the

individual dietary factors or measures of overall diet

Framework Convention on Tobacco Control mea-

quality, and there is little doubt about the importance

sures has varied widely across countries. Increasing

of dietary risks as a cause of global disease burden.

adoption and effective implementation of evidence-

Strong

commercial

interests

driving

sales

of

based tobacco control policies is a key worldwide

unhealthy foods have made it challenging to make

public health priority. Looking ahead toward non-

signiﬁcant progress toward improving diet quality.

communicable disease targets set in the Sustain-

Easy access to healthy fruits, vegetables, and whole

able Development Goals, accelerated progress in

grains remains limited for much of the world. Many

implementing proven policies and interventions is

countries have adopted policies to limit consumption

necessary

of added sugar, sodium, and harmful fats, but

to

substantially

reduce

tobacco-

attributable burden.

implementation has mostly been weak, and the
impact on global health has been limited. Exceptions

DIETARY RISKS. In GBD 2019, dietary risks comprise

are regulatory and ﬁscal interventions such as soda

the sum of adverse effects of diets in which 15 food

taxes and beverage reformulation programs that have

types are either underconsumed (fruits, vegetables,

led to lower intakes of added sugars, proving the

legumes, whole grains, nuts and seeds, milk, ﬁber,

feasibility of determined intervention. Likewise, the

calcium, omega-3 fatty acids from seafood, and

removal of artiﬁcial trans-fat from the food supply in

polyunsaturated fatty acids) or overconsumed (red

the United States has improved diet quality, although

meat, processed meat, sugar-sweetened beverages,

the amount of trans-fat in the global food supply re-

trans-fatty acids, and sodium).

mains high. Reliance on drug therapies targeting

CVDs are the primary consequence of these dietary

downstream metabolic risk factors caused by obesity

risks, with 7.94 million (95% UI: 6.47 to 9.76 million)

may be inadequate. Ill health caused by dietary risks

annual deaths and 188 million (95% UI: 156 to 225

is anticipated to rise rapidly in LMICs over the coming
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F I G U R E 2 2 Total Numbers and Rates of Dietary Risks
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(A) Total number of DALYs, deaths, YLDs, and YLLs due to dietary risks, 1990 to 2019. Shaded regions represent 95% uncertainty intervals.
(B) Age-standardized and all-ages DALY, death, YLD, and YLL rates of dietary risks, 1990 to 2019. Shaded regions represent 95% uncertainty intervals.
Abbreviations as in Figure 1.
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years, and behavioral and policy interventions suited

North America; and for women in Andean Latin

for implementation at scale in diverse settings around

America.

the world are urgently required.

LPA remains a major threat to public health, and

LOW PHYSICAL ACTIVITY. LPA is an important risk

factor for IHD, stroke, diabetes, breast and colon
cancers, and other noncommunicable diseases. The
combination of increased risk for important causes of
mortality and signiﬁcant levels of LPA in most countries has led to physical inactivity being characterized
as a pandemic. LPA is an important contributor of
premature mortality, morbidity, and DALYs for adults
in most of the world.
Globally, the total number of DALYs due to LPA,
deﬁned as <3,000 to 4,500 metabolic equivalent minutes per week, continuously increased from 8.61
million (95% UI: 4.28 to 15.9 million) in 1990 to 15.7
million (95% UI: 8.52 to 28.6 million) in 2019

the overall burden is increasing globally even as agestandardized rates are declining. Although few health
systems have historically focused on LPA, there is
increased awareness and attention being paid to LPA
as exempliﬁed by the 2018 World Health Organization
Global Action Plan for Physical Activity. However, the
factors that inﬂuence population physical activity
largely reside outside of the health sector. Increasing
physical activity will depend on effective partnerships and collaboration between health and sectors
such as transportation, education, urban planning,
workplace

health

strategies,

and

environmental

protection.

SUBNATIONAL DISEASE BURDEN

(Supplemental Figure 63A). A linear trend was
observed in the numbers of deaths due to LPA, reach-

GBD 2019 estimates disease burden within countries

ing 832,000 premature deaths (95% UI: 427,000 to

as well as between countries. Figure 24 shows the

1,470,000 premature deaths) in 2019. During the same

age-standardized rate of YLLs due to CVD for all

time period, the estimated YLLs grew steadily from

countries, with Brazil, China, India, Indonesia, Japan,

7.51 million (95% UI: 3.62 to 14.4 million) in 1990 to 12.7

Kenya, Mexico, the United States, and the United

million (95% UI: 6.58 to 23.8 million) YLLs in 2019.

Kingdom shown at the ﬁrst subnational administra-

Over time, the all-ages rate of DALYs, deaths, and

tive level and Stockholm County shown separately

YLLs due to LPA has increased, and the age-

from the rest of Sweden. Subnational disease esti-

standardized

(Supplemental

mation is made possible through collaboration with

Figure 63B). This pattern reﬂects increased burden

these governments. Subnational data reveal wide

due to growth and aging of the population, an effect

differences in DALYs within countries. For example,

that is removed by age standardization.

in Kenya in 2019, IHD DALYs were estimated to vary

rate

has

decreased

Total global DALYs due to LPA were similar for men

from 342.7 per 100,000 (95% UI: 212.4 to 531.7 per

and women until the 65- to 69-year age group, with

100,000) in Turkana to 1,215.4 per 100,000 (95% UI:

men consistently higher (Supplemental Figure 64).

856.8 to 1,612.4 per 100,000) in Nyeri, a 112.0% dif-

This pattern reversed in the 70- to 74-year age group

ference within Kenya. IHD DALYs in India ranged

as DALYs for women surpassed those for men. At all

from 506.6 per 100,000 (95% UI: 379.6 to 819.0 per

ages beyond 75 years, women had more DALYs than

100,000) in Mizoram to 5,413.2 per 100,000 (95% UI:

men, presumably driven by greater survival among

4,316.9 to 6,389.9 per 100,000) in Punjab, a 165.8%

women. LPA DALYs rose steadily for both men and

difference within the country. In Brazil, IHD DALYs

women beginning at age 25 years, peaking for both

varied from 771.2 per 100,000 (95% UI: 679.4 to 866.3

sexes in the 80- to 84-year age group and declining

per 100,000) in Amazonas to 2,416.2 per 100,000 (95%

thereafter.

UI: 2,176.7 to 2,686.2 per 100,000) in the Rio de

Age-standardized DALYs due to LPA were highly

Janeiro state, a 103.2% difference within the country.

variable by both region and sex. The highest rates

Within the United States, there was a 99.6% differ-

were seen for both men and women in North Africa

ence in IHD DALYs, ranging from 1,438.3 per 100,000

and the Middle East, Oceania, tropical Latin America,

(95% UI: 1,210.7 to 1,699.0 per 100,000) in Utah to

and the Caribbean (Figure 23), with high rates for men

4,293.1 per 100,000 (95% UI: 3,636.0 to 5,033.0 per

also

(Supplemental

100,000) in West Virginia. In Mexico, they ranged

Figure 65). The lowest age-standardized DALYs for

from 890.5 per 100,000 (95% UI: 752.2 to 1,073.3 per

LPA were seen for both men and women in high-

100,000) in Quintana Roo to 2,315.1 per 100,000 (95%

income Asia Paciﬁc, Southern Latin America, and

UI: 1,932.1 to 2,716.3 per 100,000) in Chihuahua, an

Eastern subSaharan Africa; for men in high-income

88.9% difference within Mexico. Disease burden

observed

in

Central

Asia
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F I G U R E 2 3 Map of Age-Standardized DALYs Due to Low Physical Activity in 2019

DALYs ¼ disability-adjusted life years.

attributable to elevated levels of metabolic risk fac-

interventions and delivering resources where they

tors also varies signiﬁcantly within countries.

will have the biggest impact. There is often a gap

Further analysis of the variation of CVD burden

between the identiﬁcation of a problem, the location

within countries will be vital to implementing health

of a solution, and the translation of that solution to

policies that reduce burden but also decrease dis-

an entire population. We currently lack a systematic,

parities. The strategies to deal with these inequalities

scalable process for determining which interventions

include: 1) targeting reduction in key modiﬁable risks

are most likely to succeed in a given location, and

including diet, tobacco, alcohol, physical activity, and

research funding should be directed at addressing

obesity; 2) improved access and quality of health care;

this gap.

and 3) a renewed focus on the social determinants of
health. Addressing risk factors may prove to be an

STUDY LIMITATIONS

important initial opportunity to reduce disparities in
parallel with broader efforts targeting social de-

Estimates from GBD 2019 should be interpreted in

terminants, with potential indirect beneﬁts for

light

improving those social determinants, such as reduced

although an essential source of data for public

of

several

limitations.

Death

certiﬁcates,

ﬁnancial hardship due to fewer acute cardiac events

health, may be misclassiﬁed given the difﬁculty of

among working-age adults.

identifying an underlying cause of death. GBD 2019

Several risks are increasing globally and warrant

applies statistical methods to improve the compa-

system

attention,

rability of health information coded using the ICD

pressure,

unhealthy

system and continuously evaluates, improves on,

cholesterol, and poor diet. Targeting subnational

and reports the details of these methods. The use of

locations where metabolic risks are rising rapidly

different subnational population-based studies may

may be an important approach for testing new

lead to compositional bias of national estimates,

increased

policy

and

health

including high BMI, blood
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F I G U R E 2 4 Map of Age-Standardized YLLs Due to Cardiovascular Diseases in 2019

YLLs ¼ years of life lost.

although GBD 2019 adjusts variance and weighting

particular, better data are needed on the incidence

to reﬂect this possibility. ICD system codes from

of coronary events, cardiac arrest, and the severity

administrative health facility data may represent a

and associated disability of chronic heart and

group of patients that differs from the standard case

vascular diseases. Comorbidity of CVD and the joint

deﬁnition for a disease, although GBD 2019 applies

effects of multiple risk factors remains a topic

adjustments to these data to account for differential

where further investigation is also needed.

access to health care and alternate case deﬁnitions.
Access to CVD diagnostic technologies is likely to

CONCLUSIONS AND RECOMMENDATIONS

inﬂuence estimates of some conditions, with lower
access resulting in lower observed prevalence. Some

CVDs remain the leading cause of disease burden in

commonly

example,

the world. CVD continues its decades-long rise for

electrocardiogram for AF—will underestimate true

almost all countries outside the high-income world

disease prevalence. Estimates are reported with an

and, alarmingly, age-standardized CVD rates have

uncertainty interval that should always be carefully

begun to rise in many locations where they were

considered, given that it represents both data

previously declining. There remains a large gap be-

sparsity and differences in sample size across data

tween identifying CVD as a problem, identifying the

sources and study locations. However, uncertainty

best package of solutions, and delivering them to the

may be underestimated in locations where no data

entire population.

used

diagnostic

tools—for

on CVD of any kind are available. Limited data on

GBD 2019 continues to be a platform that allows

CVD and resulting wider uncertainty intervals for

tracking and benchmarking of progress in the reduc-

parts of sub-Saharan Africa, Oceania, and Asia may

tion of CVD burden. However, large investments are

restrict our ability to interpret trends in burden

still

over time. An important use of GBD results is

including the expansion of robust vital registration

therefore to identify gaps in CVD health data and

systems, reliable electronic health records, and health

guide investments in future disease surveillance. In

surveys to all countries.

needed

to

improve

disease

surveillance,
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